3Vote!
Xconomy (Free subscription) | 20/11/2009
[Update: 1:55 pm Eastern, 11/20/09] After a bitter standoff earlier this year with billionaire investor Carl Icahn over alleged mismanagement, Cambridge, MA-based Biogen Idec now faces another sharp attack from a major shareholder. New York-based HealthCor Management, a hedge fund that invests in health and biotech companies, said today in a regulatory filing that Biogen (NASDAQ: [...]
3Vote!
The Boston Business Journal (Free subscription) | 20/11/2009
One of Biogen Idec Inc.’s largest investors is criticizing chief executive James Mullen’s compensation package and other corporate spending initiatives in an effort to goad the company into boosting its stock performance.
4Vote!
Medical News Today (Free subscription) | 20/11/2009
Genentech, Inc., a wholly-owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and Biogen Idec (Nasdaq: BIIB) announced today that the U.S. Food and Drug Administration (FDA) issued a complete response on the companies' applications for Rituxan® (rituximab) plus fludarabine and cyclophosphamide (FC) for the treatment of people with previously untreated and previously treated chronic lymphocytic...
3Vote!
Xconomy (Free subscription) | 19/11/2009
Few doctors knew much about a rare brain infection called PML back in 2005, when two patients on a hot new multiple sclerosis drug from Biogen Idec and Elan died from the side effect. The infection, at the time, was generally considered a death sentence. But now with three years of data from more than [...]
3Vote!
Star Tribune (Free subscription) | 18/11/2009
Neither company disclosed the specific nature of the FDA's "complete response letter," which is typically a request for some type of information or input. The companies did say the FDA is not asking for new data on the drug and that it is still in discussion over the drug's labeling.
3Vote!
Seattle Post-Intelligencer (Free subscription) | 18/11/2009
NEW YORK -- Genentech Inc. and partner Biogen Idec Inc. said Wednesday the Food and Drug Administration is withholding a decision to expand approval of Rituxan as a leukemia treatment, pending further discussion.
3Vote!
San Fransisco Chronicle (Free subscription) | 18/11/2009
Genentech Inc. and partner Biogen Idec Inc. said Wednesday the Food and Drug Administration has asked for more information before considering approving Rituxan as a leukemia treatment. The drug is already approved as a treatment for rheumatoid arthritis and... BiogenIdec - Food and Drug Administration - Genentech - Rituximab - Health
3Vote!
Business Wire (Free subscription) | 18/11/2009
SOUTH SAN FRANCISCO, Calif. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genentech, Inc., a wholly-owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and Biogen Idec (Nasdaq: BIIB) announced today that the U.S. Food and Drug Administration (FDA) issued a complete response on the companies’ applications for Rituxan® (rituximab) plus fludarabine and cyclophosphamide (FC) for the treatment...
3Vote!
Law Blog - WSJ.com (Free subscription) | 18/11/2009
Activity in Biogen Idec jumped to twice the normal level, after traders elected to sell 'straddles' in the firm's options.
3Vote!
10Q Detective (Free subscription) | 13/11/2009
In the battle for market share and sales, Biogen Idec (BIIB-$46.75) has successfully conveyed the Tysabri message to providers and potential customers alike through popular social media websites ranging from YouTube to Facebook. Despite the increasing amount of PML cases that have been diagnosed since Tysabri was re-introduced to the U.S. market in July 2006, neurologists’ confidence in the drug...
3Vote!
The Earth Times Online Newspaper (Free subscription) | 10/11/2009
CHICAGO - Zacks.com releases the latest Industry Outlook. Today, Zacks Equity Research discusses the Big Pharma & Biotech Industry, including Alcon (NYSE:
Click here to see all comments
MAXIDEX DEXAMETHASONE WARNING
I had eye surgery and in the post-op pack was MAXIDEX(dexamethasone) drops by ALCON LABS.
Two days later I was BLIND
Use Google and enter EPOCRATES...
anonymous - 12/11/2009
3Vote!
Business Wire (Free subscription) | 10/11/2009
CHICAGO--(BUSINESS WIRE)--Zacks.com releases the latest Industry Outlook. Today, Zacks Equity Research discusses the Big Pharma & Biotech Industry, including Alcon (NYSE: ACL), Novartis (NYSE: NVS), Gilead Sciences (Nasdaq: GILD), Biogen Idec (Nasdaq: BIIB) and Acorda Therapeutics (Nasdaq: ACOR). A synopsis of today’s Industry Outlook is presented below. The full article can be read at http://www.zacks.com/stock/news/27081/Big+Pharma+and+Biotech....
Click here to see all comments
MAXIDEX DEXAMETHASONE WARNING
I had eye surgery and in the post-op pack was MAXIDEX(dexamethasone) drops by ALCON LABS.
Two days later I was BLIND
Use Google and enter EPOCRATES...
anonymous - 12/11/2009
3Vote!
Business Wire (Free subscription) | 10/11/2009
CAMBRIDGE, Mass.--(BUSINESS WIRE)--First graph, first sentence of release dated November 9, 2009, should read: ...Friday, November 13, 2009 at 8:30 a.m. MST, 10:30 a.m. EST. (sted ...Friday, November 13, 2009 at 8:30 a.m. MST, 6:30 a.m. EST.). The corrected release reads: BIOGEN IDEC TO PRESENT AT THE 2009 ANNUAL CREDIT SUISSE HEALTHCARE CONFERENCE Biogen Idec Inc. (NASDAQ:BIIB) announced today that...
Videos